ESM1: A Potential Drug Target and Biomarker for Angioedema (G11082)

Target Name: ESM1

NCBI ID: G11082

ESM1: A Potential Drug Target and Biomarker for Angioedema

Angioedema is a type of skin reaction that occurs as a result of increased inflammation in the subdermal tissue of the body. It is characterized by sudden, local swelling of the face, neck, and other parts of the body, and can be accompanied by itching , redness, and discomfort. This condition is typically caused by an underlying inflammatory response, and can be triggered by a variety of factors, including stress, exercise, and medication.

One potential drug target for angioedema is ESM1, a molecule that is expressed in high levels in the endothelial cells that line the blood vessels. These cells play a crucial role in maintaining the blood supply to the body's tissues, and their dysfunction can be a hallmark of various diseases, including cardiovascular disease and cancer.

ESM1 has been shown to be involved in a number of physiological processes that are important for maintaining the health and function of the endothelial cells. For example, it has been shown to promote the formation of new endothelial cells, which are essential for maintaining the blood supply to the body's tissues. It has also been shown to regulate the production of growth factors, which are important for cell growth and maintenance.

In addition to its role in cell maintenance, ESM1 has been shown to play a key role in the regulation of angioedema. Studies have shown that high levels of ESM1 are associated with increased inflammation in the endothelial cells, which can contribute to the development of angioedema . Additionally, treatments that are effective in reducing inflammation in these cells have been shown to be effective in reducing the severity and duration of angioedema.

As a potential drug target, ESM1 is an attractive target for the development of new treatments for angioedema. By inhibiting the activity of ESM1, researchers hope to reduce inflammation in the endothelial cells, which can improve blood flow to the body's tissues and reduce the risk of angioedema.

In addition to its potential as a drug target, ESM1 is also a potential biomarker for angioedema. The inflammation that is associated with ESM1-expressing tissues and the production of inflammatory mediators such as cytokines and growth factors can be detected by detecting these biomarkers. Diagnose and monitor disease progression. This will help doctors better understand the progression of the disease and the effectiveness of treatment, and provide better treatment options for patients.

Overall, ESM1 is a promising candidate as a drug target for angioedema. The evidence suggests that it plays a crucial role in the regulation of endothelial cell function, and that its dysfunction is associated with the development of angioedema. Further research is needed to fully understand its role and potential as a drug target and biomarker for this condition.

Protein Name: Endothelial Cell Specific Molecule 1

Functions: Involved in angiogenesis; promotes angiogenic sprouting. May have potent implications in lung endothelial cell-leukocyte interactions

More Common Targets